

ERLEADA (apalutamide, oral)

Diagnoses Considered for Coverage:

- Non-metastatic castration-resistant prostate cancer (nmCRPC)
- Metastatic castration-sensitive prostate cancer (mCSPC)

Coverage Criteria:

For diagnoses above:

For metastatic castration-sensitive disease (mCSPC)

- Not being used with Nubeqa, Xtandi, Yonsa, or abiraterone (Zytiga), **and**
- Dose does not exceed 240 mg per day, **and**
- One the following androgen deprivation therapies:
 - Currently receiving a LHRH agonist: Zoladex (Goserelin), Vantas (histrelin), Lupron (leuprolide), Trelstar (triptorelin), **or**
 - Currently receiving a LHRH antagonist: Firmagon (degarelix), **or**
 - Patient had testes removed (bilateral orchiectomy).

For non-metastatic castration-resistant disease (nmCRPC)

- Not being used with Nubeqa, Xtandi, Yonsa, or abiraterone (Zytiga), **and**
- Patient's PSA (prostate specific antigen) level rising despite androgen deprivation therapy (ADT) [GnRH therapy or testes removal), **and**
- Dose does not exceed 240 mg per day, **and**
- One the following androgen deprivation therapies:
 - Currently receiving a LHRH agonist: Zoladex (Goserelin), Vantas (histrelin), Lupron (leuprolide), Trelstar (triptorelin), **or**
 - Currently receiving a LHRH antagonist: Firmagon (degarelix), **or**
 - Patient had testes removed (bilateral orchiectomy).

Coverage Duration: one year

Effective Date: 11/29/2023